期刊
TRANSLATIONAL IMMUNOLOGY IN ASIA-OCEANIA
卷 1283, 期 -, 页码 22-29出版社
BLACKWELL SCIENCE PUBL
DOI: 10.1111/j.1749-6632.2012.06802.x
关键词
tuberculosis; biomarkers; transcriptomics; vaccination
类别
资金
- EU FP7 project NEWT-BVAC from the European Union [HEALTH-F3-2009-241745]
- EU FP7 project TRANSVAC from the European Union [FP7-INFRASTRUCTURES-2008-228403]
- EU FP7 project A-DITEC from the European Union [HEALTH-F4-2011-280873]
- European and Developing Countries Clinical Trials Partnership (EDCTP) project Collaboration and integration of tuberculosis vaccine trials in Europe and Africa (TBTEA) [MS.20120.10800.002]
- African European Tuberculosis Consortium (AE-TBC)
- Bill & Melinda Gates Foundation Grand Challenges in Global Health Program (BMGF GC6-74) [37772]
- Innovative Medicines Initiative Joint Undertaking Biomarkers for Enhanced Vaccine Safety BIOVACSAFE (IMI JU) [115308]
There is great need for better control measures for tuberculosis (TB). High-throughput analyses, such as transcriptomic and metabolic profiling, offer a promising path toward clinically useful biosignatures. With the help of biomarkers, it will be possible not only to reliably perform diagnosis but also to gain a better understanding of the disease process and, in the future, even predict the onset of disease in infected individuals. Biomarkers based on transcriptomic and metabolic profiles as well as on cytokine composition provide important insights into the basic biological principles of TB and give an opportunity to reliably distinguish TB patients from healthy individuals. Use of biomarkers for point-of-care diagnosis, however, is still a distant goal, which to achieve will require extensive analysis of TB biosignatures across different cohorts and a combination of different platforms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据